Product Candidate / PROGRAM Drug substance Indication Discovery Pre-clinical Phase 1 Phase 2 Phase 3/ Pivotal EMA/FDA review Commercial Rights
ERYZYME Therapeutic enzymes Metabolic diseases  

ERYZYME covers the application of our ERYCAPS platform to enzyme-based therapies beyond oncology. As with our lead program eryaspase, we encapsulate therapeutic enzymes in red blood cells to deliver superior outcomes through long-acting efficacy and reduced adverse reaction vs. non-encapsulated enzymes.

Under the ERYZYME approach, Erytech is currently advancing a pipeline of novel and highly differentiated programs for rare and highly specialized conditions.